This may illuminate drug effects and revealhow to more effectively exploit sodium signaling in clinical settings.Another class of sodium transporters, NKCC1, has been shown to beupregulated in metastatic hepatocellular carcinoma (HCC),94 and the inhibitor bumetanide has been demonstratedto impact tumor growth and metastases in preclinical models of HCC.81,94 The sodium-dependent glucose transporters SGLT enable the cellularuptake of glucose, representing an alternative mechanism to the canonicalpathway implicating glucose transporters (GLUTs). Here, SLC12A2 is linked to hepatocellular carcinoma.